Current characteristics and outcomes of Cytomegalovirus Reactivation in kidney transplant seropositive recipients in the era of prophylaxis treatment. Lesson from single Moroccan center experience [article]

Bouchra REZZOUK, Tarik Bouattar, Bouchra Belkadi, Rachid Razine, Rabia Bayahia, Naima Ouzeddoun, Loubna Benamar, Hakima Rhou, Najat Bouihat, Azeddine Ibrahimi, Myriam Seffar, Hakima Kabbaj
2019 medRxiv   pre-print
Despite the use of antiviral prophylaxis, the active cytomegalovirus (CMV) replication is still occurred in the seropositive kidney recipients. The aim of this study was to assess the incidence of CMV reactivation and potential risk factors associated with CMV disease. Data of sixty kidney transplant recipients who had received CMV prophylaxis were obtained between 2013 and 2017. Quantitative nucleic acid amplification testing for CMV viraemia was assessed using Abbott RealTime Polymerase Chain
more » ... me Polymerase Chain Reaction (PCR). Among the seropositive recipients, cumulative incidence for reactivation was 63%. In patients with quantitative viraemia, the time of active replication was significantly lower compared to those with detectable viraemia (141.5, SD:96.9 vs 294.1, SD: 112.6 days, P inferior to 0.001). During prophylactic treatment, 46.7% of patients with quantifiable viraemia had experienced active replication and none among patients with detectable viraemia (P= 0.017). Importantly, symptomatic reactivation was significantly observed in the younger patients with higher peak viraemia compared to those with symptoms free (28.8, SD:5.12 vs. 38.1, SD: 12.34 years, P= 0.007) and 3.8, SD: 1.59 vs. 2.4, SD: 0. 79 log10IU/ml, P = 0.003, respectively). Furthermore, the median duration of viraemia (21.2, vs. 13.4 days, P= 0.028) and period of CMV therapy (24.3 vs 12.3 days, P inferior to 0.001) were significantly longer for this group. In addition, intercurrent infections (75% vs. 23%, P = 0.028 ) and acute rejection (50 % vs 0%, P = 0.003) were significantly more frequent in symptomatic reactivation group. In addition, peak viral load was a potential risk factor for development of symptomatic reactivation with odds ratio 3.39, 95%CI=1.21-9.53, P = 0.02). In conclusion, CMV reactivation remains serious problem for seropositive recipients who were expected to be on antiviral prophylaxis. Patients with high level of viraemia may be at an increased risk of progression to CMV disease and adverse outcomes.
doi:10.1101/19001008 fatcat:m4ls7hacnrgz7dvwmybh5flxya